LOS ANGELES–(BUSINESS WIRE)–Gores Metropoulos, Inc. (the “Company”), a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar […]

High Times Regulation A Offer Formally Extended to June 30; Shares Likely to List Much Sooner By John Jannarone The parent of High Times magazine has formally extended its offer […]

NEW YORK–(BUSINESS WIRE)–Pivotal Acquisition Corp. (NYSE: PVT.U) (the “Company”) announced today that it closed its initial public offering of 23,000,000 units, including the full 3,000,000 units subject to the underwriters’ […]

Initial Listing on Nasdaq Approved Begins trading under symbol WORX NEW YORK–(BUSINESS WIRE)–SCWorx, Corp. (f/k/a Alliance MMA, Inc.) (Nasdaq:WORX) announced the Company successfully completed the acquisition of SCWorx Corp. on […]

$200 Million Contract Includes Surprise Revenue That Should Boost 2019 Ebitda Another 6{efe5d79870c08482e17ab0c97855f89429dac5f22c46026d3ca83573faec2208} By John Jannarone Target Lodging, a flexible-housing operator focused in the petroleum-rich Permian Basin, has landed a […]

LOS ANGELES–(BUSINESS WIRE)–Gores Metropoulos, Inc. (the “Company”), a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar […]

Shell Company Myrexis Has $100 Million in Net Operating Losses That a Profitable Business May Use Market turmoil and the government shutdown were just the latest reasons for the fickle […]

NEW YORK–(BUSINESS WIRE)–Pivotal Acquisition Corp. (NYSE: PVT.U) (the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will commence trading […]

NEW YORK–(BUSINESS WIRE)–New Fortress Energy LLC (NASDAQ: NFE) (“New Fortress” or the “Company”) announced today the pricing of its initial public offering of 20,000,000 Class A shares representing limited liability […]

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it […]